Click Here to Visit Booth
Jeffery T. Meltzer, MD MBA, Medical Director, Natera
Melissa Maisenbacher, MS, CGC Associate Director, Clinical Projects, Natera
With Practice Bulletin 226 supporting that NIPT should be offered to all pregnant patients, the differences between test offerings can be difficult to wade through. We’ll examine the advantages of available tests, along with the support services that can help expand testing to all of your patients. In addition, we’ll take a look at results from the groundbreaking SMART (SNP-based Microdeletion and Aneuploidy Registry Trial) study, the largest prospective NIPT study to date, and its potential impact on prenatal screening requirements and pregnancy management.